Intellectual property, pharmaceutical MNEs and the developing world

Ghauri, Pervez N.; Rao, P.M.
April 2009
Journal of World Business;Apr2009, Vol. 44 Issue 2, p206
Academic Journal
Abstract: The paper examines the structure of pharmaceutical R&D funding, spillovers and public�private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives of preserving incentives for the multinational enterprise (MNE) innovation and making patented drugs accessible to the poor countries at affordable prices. The paper argues for a vastly expanded size and scope of public-academic-nonprofit funding of R&D, whose results could become a global public good. Finally, the paper suggests that the international business scholars further explore the implications of the strong private�public-academic linkages found in the pharmaceutical research combined with the trends towards open innovation and economic development.


Related Articles

  • Presidential Messaging, Innovation, and Intellectual Property. DAMES, K. MATTHEW // Information Today;Apr2011, Vol. 28 Issue 4, p24 

    The article examines U.S. President Barack Obama's 2011 State of the Union address on January 25, 2011, stressing the role of American innovation and creativity to U.S. economy and the necessity of protecting its intellectual property (IP). It mentions organizations like the General Agreement on...

  • Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. Morag-Sela, Tamar; Cohn, Ilan; Kowalski, Thomas J.; Jarecki-Black, Judy; Clyde-Watson, Zoe // Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1591 

    The article discusses issues related to intellectual property (IP) rights to pharmaceuticals in Israel. The country has a very strong generic pharmaceutical industry. Israel's past record of defending and respecting IP rights has led major companies around the world to file patent applications...

  • Caution needed for Russian Expansion.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p10 

    The article indicates that accounting and consulting firm PricewaterhouseCoopers has released a report on the opportunities and problems associated with the pharmaceutical industry in Russia. It was observed that the legal system is much weaker than in the European Union, U.S. or Japan, and that...

  • Limits in Intellectual Property Protection. Münch, Vera // Online;Sep/Oct2011, Vol. 35 Issue 5, p34 

    The article discusses the highlights of the 2011 PATINFO conference held in Ilmenau, Germany. The theme for the year was "Boundaries and Borders of Intellectual Property (IP) Protection." The conference addressed problems relating to patent and trademark legislation, and IP protection systems in...

  • Research Spotlight: Multinational Enterprises and International Technology Transfer. Zeile, William J. // Survey of Current Business;Sep2014, Vol. 94 Issue 9, p1 

    The article focuses on the international technology transfer and multinational enterprises in U.S. Topics discussed include the study on firm's international diffusion of knowledge, reforms in intellectual property rights protection, and the study on the situations that enhance multicountry...

  • SPECIFIÄŒNOSTI ZAÅ TITE PRAVA INTELEKTUALNE SVOJINE U OBLASTI BIOTEHNOLOGIJA. Šarac, Jovan // Singidunum Scientific Review / Singidunum Revija;2011, Vol. 8 Issue 1, p339 

    The dynamic development of modern biotechnology called into question the standard patent model, which has been predominant in comparative patent law for a long time. Biotechnology of micro organisms entered into the sphere of patent law rather early, whereas it was not the case with...

  • A co-evolutionary perspective on the drivers of international sourcing of pharmaceutical R&D to India. Haakonsson, Stine Jessen; Jensen, Peter D. Ørberg; Mudambi, Susan M. // Journal of Economic Geography;Jul2013, Vol. 13 Issue 4, p677 

    The attractiveness of the Indian pharmaceutical industry as a destination for R&D sourcing by multinational corporations (MNCs) has evolved over the past decades. This evolution has coincided with changes in MNC strategies regarding sourcing location and governance modes. We propose a...

  • Caracterização da trajetória de desenvolvimento da indústria farmacêutica na Índia: elementos para aprendizado. Radaelli, Vanderleia; Paranhos, Julia // Parcerias Estratégicas;jun2013, Vol. 18 Issue 36, p9 

    Lately, certain developing countries have managed to gain important market shares in the pharmaceutical industry. While in many of these the strategies, governance and regulatory system for innovation are still being consolidated, this group of countries nevertheless has attracted the interest...

  • Israel Pharmaceuticals and Healthcare Report Q4 2011 -- Israel Now Reinstated on the Pharmaceutical Research and Manufacturers of America Special 301 Submission's Priority Watch List For 2011.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p538 

    The article discusses the reinstatement of Israel on the 2011 priority watch list of the Pharmaceutical Research and Manufacturers of America's Special 301 submission report. It mentions that the country magnifies high per-capita on pharmaceutical spending. It also notes that multinational firms...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics